A venture capital firm based in Southern California is actively making early-stage investments in all sectors of healthcare. The firm is currently investing from their first fund, through which the firm will invest in 25-40 companies over the next 3-5 years. To date, the firm’s current portfolio includes over 25 companies. The firm’s typical size of initial investment is $100-500K in the form of equity, convertible note, among other monetary vehicles. The firm focuses on Seed to Series A-stage companies that are based in Southern California, but opportunistically invest across all of USA and the world.
The firm invests in medical device, diagnostics, and digital health companies, but will generally not invest in therapeutics or biopharmaceuticals. The firm is opportunistic and will consider all promising technologies within the aforementioned sectors.
The firm generally invests in companies with a pre-money valuation less than $10M, but is capable of participating in investments in larger companies. The firm likes to companies within 6 months of FDA clearance or approval, or revenue generation. The firm is open to working with small/inexperienced management teams and is agnostic with regards to management team requirements. The firm is an active investor who selectively serve on boards, and actively engages their LPs who have healthcare subject matter expertise.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment